KnE Life Sciences
ISSN: 2413-0877
The latest conference proceedings on life sciences, medicine and pharmacology.
Construction Hybrid immunoglobulin All Four Dengue serotype Using Mesenchymal Stem
Published date: Dec 03 2017
Journal Title: KnE Life Sciences
Issue title: The Veterinary Medicine International Conference (VMIC)
Pages: 520-527
Authors:
Abstract:
The dengue virus is a member of vector-borne diseases that causes zoonotic disease and spreads rapidly in the world. No single treatment or vaccine yet is available that is recommended and there is no correlation with protectiveness against this disease. The heavy chain (VH) and light chain (VL) variables are molecules of immunoglobulin G (IgG) is the smallest part of the antibody. Although the part-time domain variable is short, it can be used as a long-term and rapid immune booster in the immune system. In this study we tried to clone an encoding gene that was able to influence the adaptive immune response to dengue 1-4 by using MSC as a gene carrier. The target scFv-IgG gene has been successfully integrated into the plasmid. Plasmids that we have linearly transfected into the MSC. From the cDNA synthesis results continued with PCR synthesis with primer FGHV and RGHA obtained bands in accordance with the target of 404 bp. The scFv gene encoding IgG can be integrated with MSC
Keywords: immunetherapy; dengue; hybrid; scFv-IgG; mesenchymal
References:
[1] WHO (World Health Organization). 2009.Dengue Guidelines fod Diagnosis, Treatment, Prevention and Control.
[2] Guabiraba, Rodrigo and B. Ryffel. 2013. Dengue Virus Infection: Current Concepts in Immune Mechanisms and Lessons from Murine Models. France. Immunology, 141, 143–156.
[3] Brekke OH, Sandlie I .2003. Therapeutic antibodies for human diseases at the dawn of the twenty-Wrst century. Nat Rev Drug Discov 2(1):52–62. doi:10.1038/nrd984.
[4] Base,l Matthew T, Shrestha, Tej B, Bossmann , Stefan H & Troyer, Deryl L. 2014. Cells as delivery vehicles for cancer therapeutics. Therapeutic Delivery May 2014 ,Vol. 5, No. 5, Pages 555-567 , DOI 10.4155/tde.14.24(doi:10.4155/tde.14.24)
[5] Le Blanc.K, L. Tammik, B. Sundberg, S.E. Haynesworth, O. Ringden. 2003. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol, 57 (1) (2003), pp. 11–20
[6] Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS. 2009. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One. 2009 Dec 15; 4(12):e8314.
[7] Balyasnikova IV, Franco-Gou R, Mathis JM, Lesniak MS. 2010. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med. 2010 Jun; 4(4):247-58.
[8] Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. 2007. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 2007 Dec 15; 67(24):11687-95.
[9] Le Blanc K, Ringdén O. 2007.Immunomodulation by
mesenchymal stem cells and clinical experience. J Intern Med.
2007 Nov; 262(5):509-25.
[10] Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F.
2008. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008 May; 15(10):730-8.
[11] Lim JH, Lee MH, Yi HG, Kim CS, Kim JH, Song SU. 2010. Mesenchymal stromal cells for steroid-refractory acute graft- versus-host disease: a report of two cases. Int J Hematol. 2010 Jul; 92(1):204-7.
[12] Martino G, Franklin RJ, Baron Van Evercooren A, Kerr DA, Stem Cells in Multiple Sclerosis (STEMS) Consensus Group. 2010. Stem cell transplantation in multiple sclerosis: current
status and future prospects. Nat Rev Neurol. 2010 May;
6(5):247-55.
[13] Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, Cho
CS. 2008. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol. 2008 Aug; 153(2):269-76.
[14] Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. 2008. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells. 2008 Jan; 26(1):99-107.
[15] Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. 2010. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010 Apr 26; 5(4):e10088.
